Objective: Progression-free survival is an often-used endpoint in clinical trials comparing preoperative therapy and surgery-first therapy. Because the surgery date is always later in the preoperative arm than in the surgery-first arm, it is difficult to define progression-free survival optimally. We evaluated three progression-free survival definitions that used different methods to handle incomplete resection. Methods: The three definitions specify the event date of incomplete resection (IR) as follows: 'IR ¼ event' method, date of surgery; 'IR not event' method, date of radiological or clinical progression after incomplete resection; landmark method, landmark time. According to these definitions, the theoretical strengths and weaknesses of the three definitions are investigated. Three patterns of progression-free survival and overall survival were estimated using the data of the Japan Clinical Oncology Group studies. Results: Theoretically, 'IR ¼ event' inflates alpha error while 'IR not event' method and landmark method reduce the statistical power under the alternative hypothesis. In JCOG9907, hazard ratios for the three definitions were: 'IR ¼ event', 0.80 (95% confidence interval, 0.59 -1.07; P ¼ 0.13); 'IR not event', 0.81 (95% confidence interval, 0.60 -1.09; P ¼ 0.16); landmark, 0.80 (95% confidence interval, 0.59 -1.07; P ¼ 0.15). No P value of any methods corresponded with the positive result for overall survival (P ¼ 0.03). In the preoperative arms of the four studies, maximum differences in median and percentage of 1 year progressionfree survival among the three definitions were 0-6.4 months and 1.2 -5.2%. Conclusions: Progression-free survival sometimes fails as a surrogate of overall survival, and differences among results obtained with various progression-free survival definitions can be large. Overall survival should be used as primary endpoint in studies evaluating preoperative therapy.
INTRODUCTION
Progression-free survival (PFS) and disease-free survival (DFS) are common surrogate endpoints for overall survival (OS) that are used to evaluate the efficacy of cancer therapy, and are sometimes used as primary endpoints (1 -4) . DFS after adjuvant chemotherapy in colon cancer (5) and PFS following first-line chemotherapy in advanced colorectal cancer (6, 7) have proved to be good surrogate endpoints for OS in meta-analyses. For other diseases, however, few studies have demonstrated that either PFS or DFS is a good surrogate endpoint for OS (8) . Recently, PFS has been used as a primary endpoint in some clinical trials comparing a preoperative therapy with a surgery-first therapy, but the definition of PFS varies among the published trials (9 -11) .
Generally speaking, incomplete resection (IR) is regarded as a PFS event on the date of surgery, because patients cannot usually be cured after IR. In a clinical trial comparing a preoperative therapy with a surgery-first therapy, however, regarding IR as an event on the surgery date may give rise to a lead-time bias because the date of surgery is always later in the preoperative therapy arm than in the surgery-first arm. If a patient with advanced disease that is difficult to resect completely is registered in such a study, the PFS event will occur on the date of surgery just after randomization in the surgery-first arm, whereas the event will be delayed until after preoperative therapy in the preoperative therapy arm. In spite of the lead-time bias, this PFS definition is still used in some studies (10, 12) .
To avoid lead-time bias, some researchers have defined radiologically or clinically diagnosed progression after surgery, rather than IR on the surgery date, as an event (13 -15) . Another approach used to avoid lead-time bias is the landmark method in which IR or progression from registration to the specified time (landmark time) is regarded as an event at the landmark time (16) (17) (18) .
These three PFS definitions are commonly used in clinical trials comparing a preoperative therapy with a surgery-first therapy, but all three have both methodological strengths and weaknesses. In this study, we summarize the strengths and weaknesses of the three definitions and compare the three types of PFS with OS in terms of surrogacy, examining whether a decision based on the result obtained with each PFS definition validly predicts OS.
The study protocol (JCOG0801-A) was approved by the Japan Clinical Oncology Group (JCOG) Protocol Review Committee.
PATIENTS AND METHODS

THEORETICAL REVIEW OF THREE DEFINITIONS OF PFS
First, strengths and weaknesses of the three definitions are reviewed from a theoretical viewpoint. The definition of PFS is the duration from randomization to the first evidence of progression or death from any cause. Progression included either radiologically diagnosed progressive disease or clinically diagnosed symptomatic deterioration. In patients alive without events, PFS will be censored at the last visit. If the disease is curatively resected, progression occurring before surgery does not necessarily lead to death, and is not defined as an event at surgery for each definition. The handling of IR differs among the three PFS definitions, as follows:
IR is defined as an event on the date of surgery.
'IR NOT EVENT' METHOD
Regardless of IR, radiologically or clinically diagnosed progression after surgery is defined as an event on the date of the radiologic or physical examination that confirms progression.
LANDMARK METHOD
IR and progression before the landmark time and after registration are both defined as events at the landmark time. Six months post-registration is commonly used as the landmark time, and is adopted in this study.
EVALUATION OF DIFFERENCES BETWEEN THE THREE DEFINITIONS
Using the above definitions, PFS was estimated in several JCOG studies. Studies that were Phase III or Phase II, contained a preoperative therapy arm, started between 1999 and 2008, and for which the primary analysis was completed were included in the analysis.
The hazard ratio and P value for each PFS definition were calculated in the Phase III studies and compared with the corresponding values for OS. To be a good surrogate endpoint for OS, the conclusion based on the PFS P value should correspond to the OS result.
In addition, median PFS and the percentage of 1 year PFS (%1 year PFS) were calculated for each of the preoperative arms of the Phase III and Phase II studies, and the differences between the PFS estimates obtained with the three definitions were evaluated. Although various definitions were used in the studies, differences between the estimates arising from each PFS definition should be small.
STATISTICAL METHODS
Data from all registered patients were analyzed for PFS and OS on an intention-to-treat basis. Survival curves were estimated using the Kaplan -Meier method and compared using the unstratified log-rank test. Hazard ratios were calculated via Cox regression analysis. Analyses were performed using SAS software release 9.1 (Cary, NC, USA).
RESULTS
STRENGTHS AND WEAKNESSES OF THREE PFS DEFINITIONS
Strengths and weaknesses of the three PFS definitions from the theoretical view are summarized in Table 1 .
Clinicians easily understand the 'IR ¼ event' method and are usually in agreement about when an event occurs. This method shows little observation bias, but its critical weakness is lead-time bias. Under the null hypothesis, the observed date of the event is systematically different between the two arms because the date of surgery in the preoperative therapy arm is always later than that in the surgery-first arm. This favors the preoperative arm for PFS and increases the alpha error.
The 'IR not event' method can remove lead-time bias, so it is considered to be valid under the null hypothesis. However, even apparent residual disease at surgery is not regarded as an event until the date of examination. If IR directly predicts death, an OS event, this method is likely to discard important information associated with death, which means that the method reduces statistical power under the alternative hypothesis.
The landmark method can also remove lead-time bias, and is therefore valid under the null hypothesis. Its weakness is that it discards timing information about events that occur before the landmark time and reduces statistical power under the alternative hypothesis. Another problem is that there is no formal definition of the landmark time and it differs among clinical trials. Theoretically, the landmark time should be set close to the date of surgery, and the duration of preoperative therapy will vary among studies. Therefore, it may not be feasible to establish a common landmark time setting.
Each definition has strengths and weaknesses, so we applied the three definitions to actual JCOG studies as the next step.
STUDY SELECTION
Although seven studies fulfilled the inclusion criteria, three Phase II studies (JCOG0204, JCOG0210 and JCOG0405) were excluded from the analysis due to a lack of information about progression after IR. Two Phase III studies (JCOG9907 and JCOG0102) and two Phase II studies (JCOG9806 and JCOG0001) were included in the analysis.
JCOG9907 was a randomized controlled trial that showed a superiority of preoperative chemotherapy in OS compared with postoperative chemotherapy in patients with Stage II-III (UICC, fifth edition) esophageal cancer (15) .
JCOG0102 was a randomized controlled trial for patients with cervical cancer that showed preoperative chemotherapy (chemotherapy with bleomycin, vincristine, mitomycin, cisplatin followed by radical hysterectomy and postoperative radiotherapy) was inferior in OS to a standard therapy arm (radical hysterectomy plus postoperative radiotherapy) (19) .
JCOG9806 was a single-arm Phase II study that showed a favorable OS of preoperative chemoradiotherapy followed by surgery for superior sulcus non-small-cell lung cancer (20) .
JCOG0001 was also a single-arm Phase II study that showed a favorable OS of preoperative chemotherapy with irinotecan plus cisplatin followed by gastrectomy with extended nodal dissection for locally advanced gastric cancer with extensive lymph node metastasis (21) .
Data from all studies were updated in December 2007. The study profiles are shown in Table 2 .
RESULTS OF PHASE III TRIALS
In JCOG9907, IR was observed in 25 of 330 registered patients (7.6%). Figure 1 shows the OS and three types of PFS for all registered patients in this study. The hazard ratio for OS was 0.69 [95% confidence interval (CI), 0.49 -0.97; two-sided P ¼ 0.03], which indicated that the preoperative chemotherapy arm was markedly superior to the postoperative chemotherapy arm in terms of OS. The hazard ratios for the three types of PFS were 0.80 (95% CI, 0.59 -1.07; P ¼ 0.13) for the 'IR ¼ event' method, 0.81 (95% CI, 0.60 -1.09; P ¼ 0.16) for the 'IR not event' method and 0.80 (95% CI, 0.59 -1.07; P ¼ 0.15) for the landmark method. The differences among the hazard ratios were small and the P value associated with each PFS definition was not concordant with the positive OS result.
In JCOG0102, IR was observed in 13 of 134 registered patients (9.7%). Figure 2 shows the OS and three types of PFS for all registered patients in this study. The hazard ratio for OS was 1.33 (95% CI, 0.64 -2.77; two-sided P ¼ 0.44), which indicated that the preoperative therapy was inferior to the surgery-first therapy in terms of OS. The hazard ratios for the three PFS types were 0.88 (95% CI, 0.51 -1.54; P ¼ 0.66) for the 'IR ¼ event' method, 1.03 (95% CI, 0.58 -1.84; P ¼ 0.92) for the 'IR not event' method and 0.90 (95% CI, 0.51 -1.56; P ¼ 0.74) for the landmark method. All P values obtained for the three PFS methods corresponded to the negative OS result. Table 3 shows the differences in point estimates in the preoperative therapy arms of the Phase II and III trials. The maximum differences in median PFS and %1 year PFS were 898 PFS in preoperative therapy 0 -6.4 months and 1.2 -5.2%, respectively. The proportion of IR and the maximum differences of point estimates were not associated, although the proportion of IR had been considered to be one of the most critical factors influencing the differences among PFS estimates.
EVALUATION OF POINT ESTIMATES IN PREOPERATIVE THERAPY ARMS
DISCUSSION
In this study, we demonstrated that although the P values obtained for all three PFS methods corresponded to the negative OS result in JCOG0102, they were not concordant with the positive OS result in JCOG9907. In addition, all PFS hazard ratios were attenuated compared with those of OS in both Phase III studies. Since one of the benefits of using PFS is to demonstrate more statistical power, the PFS of any of the three methods was not considered to be appropriate either. Considering the results of this study, PFS is not always a good endpoint for clinical trials to compare preoperative therapy with surgery-first therapy. Even when PFS is used as an exploratory endpoint, some methodological points should be taken into consideration. Each PFS definition has both methodological strengths and weaknesses as shown in Table 1 . Given the theory that alpha error should be minimized, 'IR ¼ event' method is not acceptable. The 'IR not event' method can remove lead-time bias, but if IR directly predicts death, this method reduces statistical power under the alternative hypothesis. Also, the landmark method can remove lead-time bias, but it discards timing information about events that occur before the landmark time and reduces statistical power under the alternative hypothesis. Moreover, the definition of the landmark method differs among clinical trials (9,16 -18) and it is not realistic to define a common landmark time setting.
In deciding whether the 'IR not event' method or the landmark method is preferred, one must consider the specific clinical situation. There are generally two reasons to utilize preoperative therapy. One is improvement of resectability and the other is intensive chemointervention targeting micrometastasis before surgery. In the first case, when the disease is initially unresectable, tumor shrinkage and complete resection are key factors for achieving a complete cure. In this situation, IR has great significance and it is reasonable to regard it as an event, suggesting that the landmark method may be a better choice. On the other hand, if the protocol treatment contains postoperative chemotherapy or metastasis to other organs is more clinically meaningful than IR, the relative clinical importance of IR is diminished. In this situation, using the landmark method leads to a considerable loss of statistical power and it may be better to use the 'IR not event' method.
In JCOG9907, IR was clinically meaningful because patients diagnosed with IR are rarely cured in esophageal cancer. This supports the use of the landmark method, but another feature of JCOG9907 is that the protocol treatment 
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of the surgery-first arm included postoperative chemotherapy. From the theoretical viewpoint discussed above, it is difficult to decide which method is better in JCOG9907. In JCOG0102, because the protocol treatment of both arms contained postoperative radiotherapy, the patients with IR could be cured with this modality. In this case, the 'IR not event' method may be better because radiologically confirmed progression is more meaningful than IR. In fact, the hazard ratio of PFS for the two methods were almost same in JCOG9907, while in JCOG0102 the hazard ratio for the 'IR not event' method was closer to the hazard ratio of OS than was that of the landmark method. This result could be explained by the difference between the clinical situations.
To be an appropriate surrogate endpoint, PFS results should correspond to those of OS. Conclusions made based on the former should agree with those derived from the latter. In JCOG0102, the P value for OS was 0.44. All P values for PFS were .0.05 and corresponded to the negative OS result. In JCOG9907, P values for all three PFS methods were .0.05 and none corresponded to the positive OS result (P ¼ 0.03). From a decision-making point of view, no PFS method was appropriate as a surrogate endpoint for OS in JCOG9907.
Another property of a good surrogate endpoint is the ability to demonstrate more statistical power than the true endpoint. In JCOG9907, OS was better in the preoperative arm with a hazard ratio of 0.69, but the hazard ratios for all of the PFS methods were attenuated (0.80, 0.81 and 0.80). This may have resulted from a timing difference from progression to death between the arms, but the reason for the difference is not clear. In JCOG0102, OS was worse in the preoperative arm with a hazard ratio of 1.33, but the hazard ratios for all of the PFS methods were also attenuated toward null (0.88, 1.03 and 0.90). From the viewpoint of increasing statistical power, no PFS method was a good surrogate endpoint for OS under the alternative hypothesis.
In the present study, large differences in median PFS and %1 year PFS among the three definitions were observed in some preoperative therapy arms, and a higher percentage of IRs does not necessarily lead to a greater difference in the median PFS or %1 year PFS. Subsequent treatment such as re-operation and postoperative chemotherapy, or inaccurate diagnosis of IR may have also influenced this discordance. Therefore, PFS should be used carefully even if the percentage of IRs is small.
There are several limitations in this study. First, we evaluated only two randomized trials and two single arm trials which are available at this time. The findings we presented should be validated further in other studies comparing preoperative therapy and surgery-first therapy. Second, we did not evaluate the appropriateness to use PFS in a trial comparing two preoperative therapies. Further investigations should be warranted in such a different setting.
In conclusion, the use of PFS as a primary endpoint is not always justified and OS should be used in clinical trials to compare preoperative therapy with surgery-first therapy. The use of PFS as a primary endpoint is controversial even in usual Phase III studies and it should be more prudent, especially when the trial compares preoperative therapy and surgery-first therapy. Different PFS definitions could lead to alternative results even if the percentage of patients with IR is small. Even when PFS is used as a secondary endpoint, the definition should be selected carefully according to the specific clinical situation at hand.
